Clinical Trials Logo

Hereditary Angioedema clinical trials

View clinical trials related to Hereditary Angioedema.

Filter by:

NCT ID: NCT01359969 Completed - Clinical trials for Hereditary Angioedema

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Start date: January 17, 2012
Phase: Phase 2
Study type: Interventional

This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.

NCT ID: NCT01188564 Completed - Clinical trials for Hereditary Angioedema

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Start date: January 2011
Phase: Phase 3
Study type: Interventional

This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in Hereditary Angioedema (HAE) patients.

NCT ID: NCT01151735 Withdrawn - Clinical trials for Hereditary Angioedema

C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The study hypothesis is that treatment of Hereditary Angioedema at the time of prodromal symptoms will decrease morbidity associated with the disease

NCT ID: NCT01095497 Completed - Clinical trials for Hereditary Angioedema

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

Start date: June 7, 2010
Phase: Phase 2
Study type: Interventional

The objectives of the study are to: 1. Evaluate the safety and tolerability of CINRYZE administered by subcutaneous injection in subjects with hereditary angioedema 2. Characterize the pharmacokinetics and pharmacodynamics of CINRYZE administered by subcutaneous injection 3. Assess the immunogenicity of CINRYZE following subcutaneous administration

NCT ID: NCT01005888 Completed - Clinical trials for Hereditary Angioedema

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Start date: March 14, 2005
Phase: Phase 3
Study type: Interventional

The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.

NCT ID: NCT00997204 Completed - Clinical trials for Hereditary Angioedema

EASSI - Evaluation of the Safety of Self-Administration With Icatibant

EASSI
Start date: September 25, 2009
Phase: Phase 3
Study type: Interventional

This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.

NCT ID: NCT00914966 Completed - Clinical trials for Hereditary Angioedema

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Start date: August 31, 2009
Phase: Phase 4
Study type: Interventional

The objectives of the study were: 1. To assess the safety and tolerability of escalating doses of CINRYZE. 2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates. 3. To assess the immunogenicity of CINRYZE.

NCT ID: NCT00912093 Completed - Clinical trials for Hereditary Angioedema

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Start date: July 16, 2009
Phase: Phase 3
Study type: Interventional

This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).

NCT ID: NCT00851409 Completed - Clinical trials for Hereditary Angioedema

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

OPERA
Start date: June 2009
Phase: Phase 2
Study type: Interventional

Hereditary angioedema ("HAE") is a disease characterized by recurrent tissue swelling affecting various body locations. Recent literature shows that patients with frequent attacks may benefit from long-term prophylaxis. This study aims to evaluate the safety and prophylactic effect of weekly administrations of 50 IU/kg recombinant C1 Inhibitor ("rhC1INH").

NCT ID: NCT00748202 Completed - Clinical trials for Hereditary Angioedema

Berinert P Study of Subcutaneous Versus Intravenous Administration

PASSION
Start date: September 2008
Phase: Phase 3
Study type: Interventional

The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.) administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable. The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic study. Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert P) and than switch to the treatment not administered before.